iNFixion Bioscience won a top prize at the BIO International Convention’s Start-Up Stadium competition as it advances an NF1 treatment strategy centered on boosting function of the healthy NF1 allele. The company aims to increase neurofibromin protein output by modulating microRNA regulation rather than repairing mutations directly, which iNFixion argues is difficult given the NF1 gene’s size and mutation diversity. The approach targets specific microRNA function “exclusively in the NF1 gene” to avoid the broad off-target risks that may come with complete microRNA inhibition. iNFixion framed the strategy as designed to take advantage of the “one good allele” in NF1 patients. Recognition at the investor-judged event can improve visibility with early capital sources and partners. For rare disease investors, the win also signals ongoing appetite for allele-enhancement platforms when traditional gene editing or gene replacement routes face technical constraints.